Related Experiment Video

Updated: Apr 24, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K

Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer

David Heigener1, Martin Reck

  • 1LungenClinic Grosshansdorf, Department of Thoracic Oncology, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Woehrendamm 80, 22927, Grosshansdorf, Germany.

Expert Review of Anticancer Therapy
|September 10, 2014
PubMed

Insights

Cancer immunotherapy, particularly immune checkpoint inhibitors, shows promise for non-small cell lung cancer. This review explores the potential of these immuno-oncology agents and combination therapies.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Immune evasion is a critical factor in cancer survival and progression.
  • Advances in understanding immune escape mechanisms have driven the development of cancer immunotherapies.
  • Immuno-oncology (I-O) agents targeting immune checkpoints are central to current cancer immunotherapy strategies.

Purpose of the Study:

  • To review the rationale and potential applications of immunotherapy in managing non-small cell lung cancer (NSCLC).
  • To focus on the role of immune checkpoint inhibitors in NSCLC treatment.
  • To discuss the potential of I-O-based combination therapies for NSCLC.

Main Methods:

  • Literature review of existing studies on cancer immunotherapy and non-small cell lung cancer.
  • Analysis of clinical trial data and research findings related to immune checkpoint inhibitors.
  • Exploration of the mechanisms of immune evasion in cancer.

Main Results:

  • Immuno-oncology agents have demonstrated notable effects in various solid tumors, including NSCLC.
  • Immune checkpoint inhibitors represent a significant advancement in cancer immunotherapy.
  • Evidence supports the expanding role of I-O therapies in clinical practice.

Conclusions:

  • Immunotherapy, especially immune checkpoint inhibitors, holds significant potential for improving non-small cell lung cancer management.
  • Combination therapies involving I-O agents may offer enhanced anti-tumor immune responses.
  • Further research and clinical studies are warranted to optimize I-O strategies in NSCLC.
Keywords:
cytotoxic T-lymphocyte-associated antigen 4immune checkpoint inhibitorsimmunotherapyipilimumablung cancernivolumabnon-small-cell lung cancerprogrammed cell death protein 1

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K